Bolt Biotherapeutics Inc (BOLT) - News Archive

: At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), Bolt Biotherapeutics unveiled promising results from their Phase 1 dose-escalation clinical trial of BDC-3042. This investigational th...

: Recent advancements in the realm of immunotherapy have showcased significant potential in battling cancer due to innovative approaches that harness the immune system. This article delves into the promising preclinical...

Navigating Legal Waters: The Bolt Biotherapeutics Securities Class Action and Its Implications In recent news, Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage immuno-oncology company, has found itself at the...

New York-based law firm, Pomerantz LLP, has initiated an investigation into the claims made by investors of Bolt Biotherapeutics, Inc. (Bolt or the Company) (NASDAQ: BOLT). With rising concerns over potential misconduct...

Bolt Biotherapeutics Initiates Phase 2 Study for BDC-1001 in HER2-Positive Breast Cancer Patients Previously Treated with EnhertuREDWOOD CITY, Calif., Dec. 05, 2023 - Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a leading...